These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 21084371)
1. Drug firm's legal action against government advisers is described as "intimidation". Moynihan R BMJ; 2010 Nov; 341():c6527. PubMed ID: 21084371 [No Abstract] [Full Text] [Related]
2. Corporate responsibility for recombinant DNA activities. Berger BA Univ Toledo Law Rev; 1981; 12(4):913-24. PubMed ID: 11649592 [No Abstract] [Full Text] [Related]
3. Vaccine-related injuries: alternatives to the tort compensation system. Sturges SA St Louis Univ Law J; 1986; 30(3):919-48. PubMed ID: 11649882 [No Abstract] [Full Text] [Related]
4. Regulation of genetic engineering: less concern about Frankensteins but time for action on commercial production. Karny GM Univ Toledo Law Rev; 1981; 12(4):815-68. PubMed ID: 11649588 [No Abstract] [Full Text] [Related]
5. RU 486 and the politics of drug regulation in the United States and France. Kramnick RK Cornell Int Law J; 1992; 25():667-718. PubMed ID: 11656340 [No Abstract] [Full Text] [Related]
6. The vaccine crossroads. Wilson JF Ann Intern Med; 2003 May; 138(10):857-60. PubMed ID: 12755580 [No Abstract] [Full Text] [Related]
7. Medical experiments and the new law: in vitro fertilisation procedures, embryo experimentation and the law. Bravender-Coyle P Law Inst J; 1985; 59(1-2):63-7. PubMed ID: 12083090 [No Abstract] [Full Text] [Related]
8. Physician financial relationships in the new regulatory environment. Roberts RD Physician Exec; 1994 Nov; 20(11):50-2. PubMed ID: 10140898 [TBL] [Abstract][Full Text] [Related]
9. Does genetic engineering need genetic engineers?: should the regulation of genetic engineering include a new professional discipline? Auchincloss S Boston Coll Environ Aff Law Rev; 1993; 20(1):37-63. PubMed ID: 11652234 [No Abstract] [Full Text] [Related]
10. Light, fast, and flexible: a new approach to regulation of human gene therapy. Cregan JA McGeorge Law Rev; 2000; 32(1):261-87. PubMed ID: 15709266 [No Abstract] [Full Text] [Related]
11. Government could be sued over human experimentation problems. Maloney DM Hum Res Rep; 1996 Oct; 11(10):6. PubMed ID: 11656530 [No Abstract] [Full Text] [Related]
12. Two views on funding. Drug firm's financial support of AMA ethics campaign poses a debate. Romano M Mod Healthc; 2001 Apr; 31(17):12. PubMed ID: 11338891 [No Abstract] [Full Text] [Related]
13. The promise and peril of direct-to-consumer prescription drug promotion on the Internet. Hall TS DePaul J Health Care Law; 2003; 7(1):1-41. PubMed ID: 15468476 [No Abstract] [Full Text] [Related]
17. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing. Breslow LH Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116 [TBL] [Abstract][Full Text] [Related]
18. US radiation report fails to satisfy critics. Macilwain C Nature; 1995 Oct; 377(6549):470. PubMed ID: 7566133 [No Abstract] [Full Text] [Related]
19. Brailer resigns from HHS panel. Decision comes on heels of his firm's CalPERS deal. Conn J Mod Healthc; 2007 Jun; 37(24):12-3. PubMed ID: 17608112 [No Abstract] [Full Text] [Related]
20. Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues. Caulfield T Health Law Rev; 2005; 13(2-3):114-6. PubMed ID: 16459424 [No Abstract] [Full Text] [Related] [Next] [New Search]